Financial toxicity in a phase I/II trial of LV20.19 CAR-T cell for B-cell malignancies a longitudinal, qualitative study

Seventeen patients receiving CAR T-cell therapy were interviewed at four time points to evaluate financial burdens experienced by patients and caregivers throughout the course of treatment. Patients reported caregiving-related financial strain, insurance complexities, and travel-related expenses. Additionally, the financial stress shifted over time from access and insurance concerns to long-term planning and survivorship costs.